Jody A. Charnow

Toxicity profile and readmission rates among patients who underwent radical cystectomy and pelvic lymph node dissection following neoadjuvant pembrolizumab are in line with previously published series reporting 90-day outcomes after RC with or without neoadjuvant chemotherapy.

Adjuvant docetaxel given to men who underwent radiotherapy for intermediate- or high-risk prostate cancer and who were on androgen deprivation therapy did not lower their risk of PSA progression, a study found.

Nodal and metastatic prostate cancer at diagnosis increased after 2008, when the USPSTF recommended against PSA screening for men aged 75 or older, and again when it expanded the recommendation for all men.

In a head-to-head comparative study involving PCa patients with early biochemical recurrence following radical surgery, PSMA PET/CT had significantly higher cancer detection rates than fluciclovine PET/CT.

The proportion of men with metastatic prostate cancer who develop visceral metastases rose from 26% in 2009 to 40% in 2016, a study found.

Low-dose-rate brachytherapy, as an addition to radiation therapy and ADT, helps improve survival in high-risk prostate cancer, according to new study data.

Men who have physically demanding jobs may have a lower risk of prostate cancer than those who do not, according to study data.

Latest findings do not confirm an overall survival (OS) benefit found in a previous randomized phase 2 trial.

Study results support the role of androgens and benefits of 5-alpha-reductase inhibition in the progression of bladder cancer.